Perspective Therapeutics (CATX) News Today $2.70 +0.12 (+4.65%) Closing price 04:00 PM EasternExtended Trading$2.75 +0.05 (+1.96%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CATX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period CATX Perspective Therapeutics, Inc.May 29 at 5:33 PM | seekingalpha.comJanus Henderson Group PLC Has $57,000 Stake in Perspective Therapeutics, Inc. (NYSE:CATX)Janus Henderson Group PLC cut its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 99.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,839 shares of the company's stocMay 27 at 3:37 AM | marketbeat.comPerspective Therapeutics, Inc. (NYSE:CATX) Receives $12.50 Average PT from AnalystsMay 27 at 3:31 AM | americanbankingnews.comPerspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of "Buy" by BrokeragesPerspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has earned a consensus rating of "Buy" from the eleven analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and tMay 26 at 2:57 AM | marketbeat.comHC Wainwright Has Pessimistic Outlook of CATX Q3 EarningsPerspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2025 earnings per share estimates for Perspective Therapeutics in a research note issued to investors on Monday, May 19th. HC Wainwright analyst R. Burns now forecasts that theMay 23, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Outlook for CATX EarningsMay 23, 2025 | americanbankingnews.comQ1 Earnings Forecast for CATX Issued By HC WainwrightPerspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Perspective Therapeutics in a report issued on Monday, May 19th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($0.32) pMay 22, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for CATX Q1 Earnings?May 22, 2025 | americanbankingnews.comPerspective Therapeutics’ SWOT analysis: rare disease stock faces clinical hurdlesMay 21, 2025 | investing.comPerspective Therapeutics, Inc. (CATX): Analysts See 460% Upside PotentialMay 21, 2025 | insidermonkey.comVelan Capital Investment Management LP Purchases New Stake in Perspective Therapeutics, Inc. (NYSE:CATX)Velan Capital Investment Management LP acquired a new position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 500,000 shares of tMay 21, 2025 | marketbeat.comBalyasny Asset Management L.P. Invests $418,000 in Perspective Therapeutics, Inc. (NYSE:CATX)Balyasny Asset Management L.P. purchased a new stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 130,914 shares of the company's stock, vaMay 19, 2025 | marketbeat.comSphera Funds Management LTD. Lowers Holdings in Perspective Therapeutics, Inc. (NYSE:CATX)Sphera Funds Management LTD. trimmed its holdings in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 21.9% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 460,247 shares of the company's stock after selling 129,048 shares during thMay 18, 2025 | marketbeat.comCubist Systematic Strategies LLC Invests $834,000 in Perspective Therapeutics, Inc. (NYSE:CATX)Cubist Systematic Strategies LLC bought a new position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 261,474 shares of the companMay 17, 2025 | marketbeat.comTruist Financial Keeps Their Buy Rating on Perspective Therapeutics (CATX)May 16, 2025 | theglobeandmail.comOctagon Capital Advisors LP Grows Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX)Octagon Capital Advisors LP grew its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 62.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,304,752 shares of the company's stock afterMay 15, 2025 | marketbeat.comPerspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 ResultsMay 14, 2025 | finanznachrichten.deSchonfeld Strategic Advisors LLC Sells 423,123 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)Schonfeld Strategic Advisors LLC reduced its holdings in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 71.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 168,500 shares of the company's stock after selling 423,123 shares during theMay 13, 2025 | marketbeat.comPerspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 ResultsMay 12, 2025 | globenewswire.comPerspective Therapeutics, Inc. (NYSE:CATX) Shares Bought by Deerfield Management Company L.P. Series CDeerfield Management Company L.P. Series C boosted its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 4.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,938,May 10, 2025 | marketbeat.comJPMorgan Chase & Co. Boosts Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX)JPMorgan Chase & Co. raised its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 498.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 149,045 shares of the company's stock after buying an additional 124,133 sMay 3, 2025 | marketbeat.comPerspective Therapeutics to Participate in Upcoming May Investor ConferencesMay 1, 2025 | globenewswire.comPerspective Therapeutics, Inc. (NYSE:CATX) Given Average Recommendation of "Buy" by BrokeragesShares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) have been assigned an average recommendation of "Buy" from the eleven analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, seven have given a buy rating and three havApril 30, 2025 | marketbeat.comPerspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid TumorsApril 29, 2025 | finance.yahoo.comPerspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Marshall Wace LLPMarshall Wace LLP lessened its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 45.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 807,172 shares of the company's stock after selling 683,619 shares durinApril 29, 2025 | marketbeat.com215,725 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Bought by Jump Financial LLCJump Financial LLC bought a new stake in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 215,725 shares of the company's stock, valued at approximatelyApril 25, 2025 | marketbeat.comTruist Financial Sticks to Their Buy Rating for Perspective Therapeutics (CATX)April 23, 2025 | markets.businessinsider.comPerspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual MeetingApril 23, 2025 | globenewswire.comWalleye Capital LLC Purchases 457,675 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)Walleye Capital LLC boosted its position in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 2,526.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 475,792 shares of the compaApril 22, 2025 | marketbeat.comPerspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Altium Capital Management LLCAltium Capital Management LLC decreased its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 68.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 92,224 shApril 20, 2025 | marketbeat.comAffinity Asset Advisors LLC Acquires 800,000 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)Affinity Asset Advisors LLC raised its holdings in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 160.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,300,000 shares of the cApril 17, 2025 | marketbeat.comPerspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial ResultsApril 17, 2025 | globenewswire.comPerspective announces first patient dosed in Phase 1/2a trial of 212PbVMT01April 11, 2025 | markets.businessinsider.comPerspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic MelanomaApril 11, 2025 | globenewswire.comIs Now The Time To Invest In Perspective TherapeuticsApril 9, 2025 | seekingalpha.comTruist Financial Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)April 9, 2025 | markets.businessinsider.comPerspective Therapeutics (NYSE:CATX) Price Target Cut to $10.00 by Analysts at Truist FinancialTruist Financial decreased their price objective on shares of Perspective Therapeutics from $21.00 to $10.00 and set a "buy" rating for the company in a research note on Monday.April 9, 2025 | marketbeat.comPerspective Therapeutics price target lowered to $10 from $21 at TruistApril 8, 2025 | markets.businessinsider.comEquities Analysts Issue Forecasts for CATX Q2 EarningsPerspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Research analysts at HC Wainwright raised their Q2 2025 EPS estimates for shares of Perspective Therapeutics in a research note issued to investors on Monday, March 31st. HC Wainwright analyst R. Burns now anticipates that the company wilApril 5, 2025 | marketbeat.comPerspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of "Buy" by AnalystsPerspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the twelve analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendaApril 5, 2025 | marketbeat.comPerspective Therapeutics, Inc. (NYSE:CATX) CEO Purchases $49,338.24 in StockPerspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) CEO Johan M. Spoor acquired 22,026 shares of the firm's stock in a transaction that occurred on Friday, March 28th. The stock was bought at an average price of $2.24 per share, with a total value of $49,338.24. Following the completion of the acquisition, the chief executive officer now directly owns 59,383 shares of the company's stock, valued at $133,017.92. This trade represents a 58.96 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.April 3, 2025 | marketbeat.comRobert F. Williamson III Purchases 22,192 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) StockPerspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) Director Robert F. Williamson III bought 22,192 shares of the stock in a transaction on Friday, March 28th. The stock was purchased at an average price of $2.27 per share, for a total transaction of $50,375.84. Following the completion of the purchase, the director now owns 70,837 shares of the company's stock, valued at approximately $160,799.99. This trade represents a 45.62 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.April 3, 2025 | marketbeat.comPerspective Therapeutics, Inc. (NYSE:CATX) CFO Juan Graham Acquires 33,333 SharesPerspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) CFO Juan Graham purchased 33,333 shares of the firm's stock in a transaction that occurred on Friday, March 28th. The stock was bought at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the transaction, the chief financial officer now directly owns 35,354 shares of the company's stock, valued at $79,546.50. This trade represents a 1,649.33 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.April 3, 2025 | marketbeat.comPerspective Therapeutics, Inc. (NYSE:CATX) Director Buys $81,630.30 in StockPerspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) Director Robert F. Williamson III purchased 38,145 shares of Perspective Therapeutics stock in a transaction on Monday, March 31st. The shares were acquired at an average cost of $2.14 per share, for a total transaction of $81,630.30. Following the completion of the transaction, the director now owns 108,982 shares of the company's stock, valued at $233,221.48. This represents a 53.85 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.April 3, 2025 | marketbeat.comJohan M. Spoor Buys 22,026 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) StockApril 2, 2025 | insidertrades.comPerspective Therapeutics (NYSE:CATX) Earns Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a report on Monday.April 1, 2025 | marketbeat.comPerspective Therapeutics to Participate in Upcoming April Investor ConferencesMarch 31, 2025 | globenewswire.comCATX Q1 EPS Forecast Lowered by Brookline Capital ManagementPerspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Research analysts at Brookline Capital Management reduced their Q1 2025 earnings estimates for shares of Perspective Therapeutics in a research note issued to investors on Wednesday, March 26th. Brookline Capital Management analyst K. DolMarch 31, 2025 | marketbeat.comResearch Analysts Issue Forecasts for CATX Q1 EarningsPerspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Lifesci Capital issued their Q1 2025 earnings per share estimates for Perspective Therapeutics in a research report issued to clients and investors on Thursday, March 27th. Lifesci Capital analyst D. Kennedy anticipates that the company wMarch 31, 2025 | marketbeat.comPerspective Therapeutics management to meet with OppenheimerMarch 29, 2025 | markets.businessinsider.com Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address CATX Media Mentions By Week CATX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CATX News Sentiment▼0.450.87▲Average Medical News Sentiment CATX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CATX Articles This Week▼64▲CATX Articles Average Week Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IRMD News RXST News EMBC News BBNX News CBLL News NPCE News AVNS News DCTH News BFLY News BVS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CATX) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
